<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761173</url>
  </required_header>
  <id_info>
    <org_study_id>18-002</org_study_id>
    <nct_id>NCT03761173</nct_id>
  </id_info>
  <brief_title>FlowTriever All-Comer Registry for Patient Safety and Hemodynamics</brief_title>
  <acronym>FLASH</acronym>
  <official_title>FlowTriever All-Comer Registry for Patient Safety and Hemodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inari Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inari Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of
      emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE). The use
      of the device will be assessed in a real-world population, with eligibility criteria that
      closely approximate its use in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 15, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Composite Major Adverse Events</measure>
    <time_frame>48-hours</time_frame>
    <description>Rate of subjects with composite of device-related death, major bleeding, device or procedure-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual Major Adverse Events</measure>
    <time_frame>48-hours</time_frame>
    <description>Rate of subjects with individual components of composite MAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30-days</time_frame>
    <description>Rate of deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related serious adverse events</measure>
    <time_frame>30-days</time_frame>
    <description>Rate of device-related SAEs</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>PE - Pulmonary Embolism</condition>
  <condition>PE - Pulmonary Thromboembolism</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FlowTriever System</intervention_name>
    <description>Thrombectomy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring thrombectomy treatment for pulmonary embolism.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs and symptoms consistent with acute PE

          -  CTPA or pulmonary angiographic evidence of proximal filling defect in at least one
             main or lobar pulmonary artery

          -  Scheduled for PE treatment with the FlowTriever System per the Investigator's
             discretion

        Exclusion Criteria:

          -  Unable to be anticoagulated with heparin or alternative

          -  Known sensitivity to radiographic contrast agents that, in the Investigator's opinion,
             cannot be adequately pre-treated

          -  Imaging evidence or other evidence that suggests, in the Investigator's opinion, the
             subject is not appropriate for mechanical thrombectomy intervention

          -  Life expectancy &lt; 30 days, as determined by Investigator

          -  Current participation in another investigational drug or device treatment study that,
             in the Investigator's opinion, would interfere with participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longstreet Clinic</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Cardiology Group</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Heart and Vascular Institute</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Heart &amp; Vascular Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cardiovascular Consultants</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Heart &amp; Vascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 28, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PE</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>thrombectomy</keyword>
  <keyword>FlowTriever</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

